Sage Journals: Discover world-class research

Abstract

Introduction

Nivolumab is s a human monoclonal antibody. Due to its widespread use in many cancers, including Merkel cell carcinoma, adverse reactions associated with nivolumab, such as neuropathies, endocrinopathies, gastrointestinal problems, and skin toxicities have been increasing. Sensory ganlionopathy is rarely observed in these patients.

Case description

We present a 63-year-old male with a medical history of Merkel cell carcinoma that recurred two times in the inguinal region. After undergoing surgery with adjuvant radiotherapy, a second surgery was performed. The patient suffered from tingling in all four limbs plus difficulty in walking after initiation of the third dose of nivolumab.

Management and outcome

After 1 month of 1 mg/kg/day methylprednisolone treatment, he showed significant improvement. Subsequently, the systemic corticosteroid regimen was tapered to 5 mg every other day. The treatment resulted in significant improvement in all extremities.

Discussion

Sensory ganlionopathy can be seen as a side effect of an immune checkpoint inhibitor, even though it is very extraordinary. This is the case in the literature to develop sensory ganlionopathy due to nivolumab. We believe that patients using nivolumab may develop sensory ganlionopathy and management should be taken on this point.

Keywords

Nivolumab ganglionopathy case report Merkel cell carcinoma side effect

Get full access to this article

View all access options for this article.

References

Clayton

Emery

. What do jays know about other minds and other times? In: Berthoz

Christen

(eds) Neurobiology of umwelt: how living beings perceive the world. Berlin: Springer-Verlag Berlin, 2009, pp.109–123.

Albores-Saavedra

, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010; 37: 20–27.

Sznol

, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 2017; 35: 3815–3822.

Spiers

Coupe

Payne

. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford 2019; 58: vii7–vii16.

Sakoh

, et al. Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC cancer 2019; 19: 1–6.

Simsek

Bilici

Tekin

. Creatinine kinase elevation and peripheral neuropathy during nivolumab treatment of a patient with metastatic renal cell carcinoma. Indian J Cancer 2018; 55: 413.

Larkin

, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017; 22: 709.

Sakai

, et al. A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis. Case Rep Med 2017; 2017: 1–4.

Iyer

, et al. Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. J Am Acad Dermatol 2016; 75: 541–547.

10.

Naranjo

Busto

Sellers

, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

11.

Amato

Ropper

. Sensory ganglionopathy. N Engl J Med 2020; 383: 1657–1662.

12.

Spain

Diem

Larkin

. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51–60.

13.

Dubey

, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019; 93: e1093–e1103.

14.

Antoine

J-C

, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci 2016; 361: 187–191.

15.

Pelosof

Gerber

. Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc 2010; 85: 838–854.

16.

Gandhi

Johnson

. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Cancer Network 2006; 4: 631–638.

17.

Greenlee

, et al. Anti-hu antibodies in merkel cell carcinoma. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 2002; 52: 111–115.

18.

Topalian

, et al. Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol: Off J Am Soc Clin Oncol 2020; 38: 2476–2487.

19.

Graus

Dalmau

. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019; 16: 535–548.

20.

Yshii

Hohlfeld

Liblau

. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 2017; 13: 755–763.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB